País: Canadá
Língua: inglês
Origem: Health Canada
FEXOFENADINE HYDROCHLORIDE
SANOFI CONSUMER HEALTH INC
R06AX26
FEXOFENADINE
60MG
TABLET
FEXOFENADINE HYDROCHLORIDE 60MG
ORAL
15G/50G
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0131730001; AHFS:
APPROVED
2021-10-18
_ALLEGRA_ _®_ _ 12 Hour (fexofenadine hydrochloride) _ _ALLEGRA_ _®_ _ 24 Hour (fexofenadine hydrochloride) _ _ALLEGRA_ _®_ _ HIVES (fexofenadine hydrochloride) _ _Page 1 of 35 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ALLEGRA ® 12 HOUR Fexofenadine hydrochloride tablets Tablets, 60 mg, Oral Manufacturer’s Standard ALLEGRA ® 24 HOUR Fexofenadine hydrochloride tablets Tablets, 120 mg, Oral Manufacturer’s Standard ALLEGRA ® HIVES Fexofenadine hydrochloride tablets Tablets, 60 mg, Oral Manufacturer’s Standard Histamine H 1 Receptor Antagonist Sanofi Consumer Health Inc. 2905 Place Louis-R. Renaud Laval, QC H7V 0A3 Date of Revision: October 5, 2021 Submission Control Number: 252314 _ _ _ALLEGRA_ _®_ _ 12 Hour (fexofenadine hydrochloride) _ _ALLEGRA_ _®_ _ 24 Hour (fexofenadine hydrochloride) _ _ALLEGRA_ _®_ _ HIVES (fexofenadine hydrochloride) _ _Page 2 of 35_ RECENT MAJOR LABEL CHANGES Patient Medication Information 04/2021 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................... 2 TABLE OF CONTENTS ...................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 4 1 INDICATIONS ......................................................................................................... 4 1.1 Pediatrics ........................................................................................................... 4 1.2 Geriatrics ........................................................................................................... 4 2 CONTRAINDICATIONS ......................................................................................... 4 4 DOSAGE AND ADMINISTRATION ............................................................................ 5 4.1 Dosing Considerations ........................ Leia o documento completo